A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Villalona-Calero
Miguel A
MA
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210-1240, USA. villalona-1@medctr.osu.edu
Ritch
Paul
P
Figueroa
Jose A
JA
Otterson
Gregory A
GA
Belt
Robert
R
Dow
Edward
E
George
Sebastian
S
Leonardo
James
J
McCachren
Spence
S
Miller
G Lance
GL
Modiano
Manuel
M
Valdivieso
Manuel
M
Geary
Richard
R
Oliver
Jennifer W
JW
Holmlund
Jon
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D015331:Cohort Studies; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use*; D009841:Oligonucleotides / Q000737:chemistry; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D051571:Protein Kinase C-alpha; D013873:Thionucleotides / Q000627:therapeutic use*; D016896:Treatment Outcome; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D020319:Oligodeoxyribonucleotides, Antisense; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D003841:Deoxycytidine; C108494:ISIS 3521; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha; D002945:Cisplatin; D000093542:Gemcitabine